CRO integration post-M&A will be very difficult; Covance

By Nick Taylor

- Last updated on GMT

Related tags Mds pharma services Contract research organization

The CEO of Covance has warned it will be “very, very difficult” for CROs expanding through M&A to integrate assets, and the process could see clients go elsewhere.

A wave of private equity-backed contract research organisation (CRO) consolidation, led by INC Research and inVentiv, has reshaped the industry, but could create problems for the buyers.

Having three different operating systems, three different IT strategies, three different leaderships and cultures, [and] three different facilities in a given region that need to be rationalised [makes it] very, very difficult​”, said Joe Herring, CEO of Covance, in a call with investors.

Throughout this process clients, concerned about the development of their potential blockbusters, are “watching every move​”. Given the high stakes some clients may choose to use other providers while the integration takes place.

I think we've seen clients take time out when they see those sort of things happen. And soI think it's going to take a while for roll-up companies to get their feet under them and compete​”, said Herring.

Mid-tier blues?

Experience of earlier integrations, such as INC’s acquisition of MDS Pharma Services’ assets, should ease and accelerate the process, and ultimately the CROs involved think the rewards outweigh the risks. For mid-tier CROs, the risk is they will struggle if they lack the scale to win big strategic deals.

We've been saying for the last several years that as pharma became more strategic in working with CROs that it was going to favour the top five players. So seeing players come together, I think, is totally expected​”, said Herring.

However, there is evidence mid-tier CROs can prosper by winning business, some of it strategic, from smaller sponsors. “Most respondents felt that smaller sponsor companies are best served by small to mid-sized providers​”, said the Avoca Group after its 2011 State of Clinical Outsourcing Survey.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

1 comment

CEO statement reveal industry-wide problem

Posted by Alric,

I find it telling that the CEO does not mention explicitly the scientists and the technicians that actually run the studies and are responsible for the study quality. His emphasis is on the leadership, IT and "operating system"; areas that are only involved in organization and do not perform the actual work.

Report abuse

Follow us

Products

View more

Webinars